AcuityMD is a Boston-based commercial intelligence platform built specifically for the medical device (MedTech) industry. It translates large volumes of healthcare claims and procedure data into intuitive workflows, AI-powered insights, and recommendations that help medical device sales and marketing teams find high-value physicians and care sites, size and segment markets, manage territories, and accelerate product adoption. Founded in 2019 by former MedTech and consulting operators, the company serves hundreds of device makers - including a majority of the largest MedTech firms - and raised an $80M Series C in 2026 at a near-$1B valuation.
Courier Health is a New York City software company building the first patient relationship management (CRM) platform purpose-built for life sciences. Its AI-powered system connects fragmented data across biopharma commercial teams to orchestrate the patient journey - from education and enrollment through benefits, prior authorization, therapy initiation, and adherence - helping patients with chronic and rare diseases start and stay on treatment. The company raised a $50M Series B led by Oak HC/FT in April 2026.
Lyfegen is a Swiss health-tech company that builds software to manage value-based drug pricing and rebate agreements. Its platform helps health insurers, governments, hospital payers, pharmaceutical firms and medical device makers automate complex rebate contracts, run pricing simulations and tap the world's largest library of value-based agreements - reducing administrative burden while helping patients access innovative therapies.
Claritas Rx is a South San Francisco-based health-tech company that turns fragmented specialty pharmacy, channel, and clinical data into actionable intelligence for biopharmaceutical manufacturers. Its AI-powered Ascend platform integrates disparate patient-level data sources so drug makers can see how their specialty and rare-disease products perform, identify access barriers, and coordinate patient support - helping more patients start and stay on therapy.